SAN DIEGO, April 19, 2017 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy
company, today announced the closing of its initial public offering
of common stock, including the underwriters' exercise of their
option to purchase an additional 1,275,000 shares at the public
offering price of $10.00 per share.
The underwriters' option brought the total number of shares of
common stock sold by Tocagen to 9,775,000 shares and increased the
amount of gross proceeds raised in the offering to approximately
$97.8 million, prior to deducting the
underwriting discount and estimated expenses of the offering.
Leerink Partners LLC, Evercore Group L.L.C. and Stifel, Nicolaus
& Company, Incorporated acted as joint bookrunning managers for
the offering.
The shares were offered by Tocagen pursuant to a registration
statement that was declared effective by the Securities and
Exchange Commission ("SEC") on April 12,
2017. A prospectus relating to and describing the terms of
the offering has been filed with the SEC and is available on
the SEC's web site at www.sec.gov. Copies of the
prospectus relating to this offering can be obtained from Leerink
Partners LLC, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, MA 02110 or by
telephone at (800) 808-7525, ext. 6132 or by email at
syndicate@leerink.com; or from Evercore Group L.L.C., Attention:
Equity Capital Markets, 55 East 52nd Street, 36th Floor,
New York, NY 10055, or by
telephone at (888) 474-0200 or by email at
ecm.prospectus@evercore.com; or from Stifel, Nicolaus &
Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104 or by telephone at
(415) 364-2720 or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy
company developing first-in-class, broadly applicable product
candidates designed to activate a patient's immune system against
their own cancer. Tocagen is developing its lead product candidate,
Toca 511 & Toca FC, initially for the treatment of recurrent
high grade glioma, a disease with a significant unmet medical need.
Tocagen has received grant support from leading brain cancer
foundations, including Accelerate Brain Cancer Cure (ABC2),
National Brain Tumor Society (NBTS), American Brain Tumor
Association (ABTA), Musella Foundation and Voices Against Brain
Cancer (VABC).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/tocagen-announces-closing-of-initial-public-offering-and-exercise-of-the-underwriters-option-300442135.html
SOURCE Tocagen Inc.